Boxed Warning In Development For Procrit, Aranesp
This article was originally published in The Pink Sheet Daily
Executive Summary
Erythropoietin marketers J&J and Amgen will participate in an FDA Oncologic Drugs Advisory Committee meeting in May.
You may also be interested in...
House Committee Calls On EPO Marketers To Provide Information, Halt DTC Ads
Inquiry also requests Amgen and Johnson & Johnson cease financial incentives to physicians.
House Committee Calls On EPO Marketers To Provide Information, Halt DTC Ads
Inquiry also requests Amgen and Johnson & Johnson cease financial incentives to physicians.
Roche Suspends Phase II Mircera Study In Chemo-Induced Anemia
Firm halts recruitment of anemic non-small cell lung cancer patients due to an “imbalance” of deaths across study arms but maintains they are not related to the drug.